TOLEDO, Ohio and MADRID–(BUSINESS WIRE)–NAMSAa world-leading MedTech contract research organization (CRO) providing end-to-end global development services, today announced its intention to acquire ÅKRN Scientific Councila leading European medical device CRO based in Madrid, Spain.
ÅKRN, founded in 2018, focuses on providing clinical and regulatory services to the medical device and diagnostic industries in Europe. Grounded in medicine and science, the organization helps sponsors move MedTech products from medical discovery through clinical development, commercialization and post-market follow-up. Recognized for their expertise in Cardiovascular researchÅKRN’s team of clinical scientists and project managers serve as a trusted customer advisor throughout the entire clinical development process through diligent planning and superior execution.
“We are delighted to welcome ÅKRN to NAMSA,” said Dr. Christophe Berthoux, CEO of NAMSA. “The organization is highly respected for its mastery of European medical device regulations and for its exceptional clinical support to MedTech sponsors. Adding them to our team will broaden our expertise, enabling us to meet the growing demand for safe and effective clinical development and commercialization of life-changing medical products,” concluded Dr. Berthoux.
As a world leader in medical devices test since 1967, NAMSA has also provided support to sponsors in the areas of regulation, reimbursement, quality and clinical research services. NAMSA is full continuous development services helps clients overcome development barriers, alleviate concerns, and streamline go-to-market efforts. Through proactive planning for various global regulatory requirements and clinical research obligations, NAMSA’s services have proven to accelerate time to market and reduce development costs by up to 50 percent on industry averages.
“ÅKRN is a great partner for NAMSA. I believe we are a perfect fit with the values of the company and a team that shares the same drive to provide exceptional service and resources to the medical device and diagnostics industries,” commented Dr. Maria Nyåkern, CEO of ‘ÅKRN. . “Our team, with strong roots in medicine and science, looks forward to partnering with NAMSA as we continue to grow our presence globally and in Europe. With the expanded expertise of our combined organizations, we will serve as the world’s leading CRO for cardiovascular research services,” concluded Dr Nyåkern.
The acquisition of ÅKRN increases the global scale of NAMSA, which now serves MedTech customers across 19 Pitches throughout APAC, Europe, North America and South America.
The price and terms of the proposed transaction are not disclosed.
Helping medical device developers improve healthcare since 1967, NAMSA is the world’s premier MedTech contract research organization (CRO) offering end-to-end global development services. Driven by its global regulatory expertise and deep therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering only the most proven solutions to move customers’ products through the development lifecycle of efficient and profitable way. Medical device testing; regulatory, reimbursement and quality advice; and clinical research services, NAMSA is the industry’s premier trusted partner for successful development and commercialization results.
The Web: namsa.com
Grounded in medicine and science, ÅKRN helps sponsors move from medical discovery to clinical development, commercialization and post-marketing follow-up. ÅKRN offers optimized regulatory and clinical services tailored to MedTech customers and partners in a cost-conscious and diligent manner. ÅKRN’s experience covers many therapeutic areas of medical devices, including cardiovascular devices and in vitro diagnostics (IVD).
The Web: akrnconsulting.com